Search Results

Onconova Therapeutics, Inc., and Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction.

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Inc. Magazine has named trailblazing life sciences company Xenco Medical one of the best companies to work for in America.

Immorta Bio Inc, a science-based Life Extension company has announced patent filing on successful treatment of the carbon tetrachloride model of liver failure using its PMSC-11 stem cell therapy.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Taysha Gene Therapies, Inc. announced that it will host a webcast on Tuesday, June 18, 2024, to discuss new clinical data from the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome, as well as provide a program update.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced updated clinical results from the ongoing investigator-sponsored Phase 2 trial of darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C, as neoadjuvant/adjuvant treatment in uveal melanoma and clinical update for Phase 2 company-sponsored neoadjuvant UM study.

Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.